Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN 002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)
NCT00101725 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN 002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)
- Lead sponsor
- Bausch Health Americas, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2004
- Completion date
- November 30, 2005
- Enrollment
- 245 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.
colonic diseases, diarrhea, gastrointestinal disease, irritable bowel syndrome